Exelixis, Inc. (EXEL) Q2 2025 Earnings Call Transcript

Exelixis reported robust Q2 2025 results, with cabozantinib franchise net product revenues growing 19% year-over-year to $520 million, fueled by strong RCC performance and a successful early launch in neuroendocrine tumors (NETs), which already contributes 4% of revenue. Strategically, the company announced positive top-line overall survival data for zanzalintinib in the STELLAR-303 colorectal cancer trial, signaling an intent to file for approval, while discontinuing the STELLAR-305 head and neck study to reallocate resources towards higher-potential zanzalintinib indications like post-adjuvant CRC and a new NET trial. This reflects a disciplined capital allocation strategy aimed at building a second major oncology franchise, supported by a strong cash position of $1.4 billion and ongoing share repurchases. The company reiterated its full-year 2025 financial guidance, noting a $147 million federal cash tax benefit from the permanent repeal of R&D capitalization requirements.

Analysis

Exelixis reported a strong Q2 2025, underscored by a 19% year-over-year increase in cabozantinib franchise net product revenue to $520 million. This growth was driven by continued market share gains in its core Renal Cell Carcinoma (RCC) indication, where it grew its share of the TKI market basket from 41% to 45%, and a highly successful early launch in neuroendocrine tumors (NETs). The NET indication contributed approximately 4% to net product revenue in its first full quarter, rapidly capturing a 35% new patient share in the oral second-line-plus segment. However, profitability faces pressure from a rising gross-to-net (GTN) deduction, which hit 30.2% due to expanding 340B program volume. Strategically, the company's pipeline for its next-generation asset, zanzalintinib, saw a pivotal development with positive top-line results from the STELLAR-303 trial, which demonstrated a statistically significant overall survival benefit in third-line colorectal cancer. This marks a key de-risking event and the first such success for an IO/TKI combination in this setting. In a clear display of disciplined capital allocation, the company simultaneously discontinued the STELLAR-305 trial in head and neck cancer to redirect resources toward opportunities with a perceived threefold greater commercial potential, such as a new pivotal trial in NETs and moving zanzalintinib into earlier-line CRC treatment. The company's financial position remains robust with $1.4 billion in cash, complemented by a $302 million share repurchase during the quarter and a future $147 million cash tax benefit from the repeal of R&D capitalization rules.

Key Decisions for Investors

• The positive overall survival data from the STELLAR-303 trial materially de-risks the zanzalintinib pipeline, and investors should now focus on the regulatory filing timeline as this asset represents the company's most significant future growth driver.
• Investors should closely monitor the revenue trajectory of the new NET indication, as its rapid 35% new patient share capture suggests it could significantly accelerate top-line growth for the cabozantinib franchise beyond the current 4% contribution.
• The decision to halt the STELLAR-305 trial, while a setback for that specific indication, should be viewed as a positive signal of disciplined capital allocation, as management is actively prioritizing assets with a higher probability of success and greater commercial value.
• While revenue growth is robust, it is critical to track the gross-to-net percentage, as management's acknowledgment that increasing 340B volume will push GTN towards 30% represents a notable and ongoing margin headwind.